Amavita Research vs. Velocity Clinical Research: which clinical trial site fits your study?

Amavita Research is a clinical trial site and PET imaging trial partner in North Miami Beach, anchored by a single dedicated cardiovascular site. The senior PI is U.S. TAVR pioneer Dr. William W. O'Neill, National PI on Edwards PARTNER, Protect II, and Protect IV. Every active study is cardiovascular, the affiliated Advanced Cardiovascular of Miami ASC supports interventional procedures on site, and processes are IAOCR GCSA-certified, valid through February 28, 2027.

Velocity Clinical Research is among the largest integrated clinical site organizations in the world, with roughly 80 sites across the U.S. and Europe, more than 220 principal investigators, and a patient database exceeding one million. It is multi-specialty by design. For sponsors that need geographic spread across many sites under a single contract, centralized operations, and database-driven recruitment at scale, that footprint is genuinely powerful.

The trade-off is depth at any one address. A network optimizes horizontally: portfolio breadth, standardized operations, and single-contract multi-site execution. A specialist site optimizes vertically: every operational dollar goes into cardiovascular research at one location - PI continuity, cardiovascular-only SOPs, and an enrollment funnel fed by an active cardiology practice.

Amavita's economics reflect that focus. There is no network overhead or MSO carve-out allocated to the protocol budget, and an anonymized 41-day contract-to-first-patient-in metric reflects what a single accountable site can do. The Miami patient population supports FDA Diversity Action Plan targets natively, and cardiac PET and radiopharmaceutical trial capability covers the emerging CV imaging-tracer pipeline.

The right model depends on the program. If the trial is multi-site by design and needs national footprint, Velocity fits. If the program needs a single deeply specialized cardiovascular site in South Florida that can move fast with named-PI accountability, Amavita fits - and many sponsors use Amavita as their lead cardiovascular site alongside network sites elsewhere.